Literature DB >> 7543582

Host cell requirements for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus.

A J Sinclair1, P J Farrell.   

Abstract

Quiescent primary B lymphocytes are efficiently immortalized by Epstein-Barr virus (EBV). This process requires both the delivery and expression of the viral genome and results in activation of the cell division cycle. Infection of B lymphocytes depends on a direct interaction between the viral glycoprotein gp340/220 and CD21, the C3dg complement receptor. This interaction is required for the adsorption of EBV. In addition, several lines of evidence suggest that the interaction of EBV with CD21 modulates the phenotype of cells. CD21 forms part of a multimeric signal transduction complex with CD19, TAPA-1, and Leu-13. In normal B lymphocytes, CD19 becomes tyrosine phosphorylated following stimulation of the antigen receptor and recruits the signal-transducing enzyme phosphatidylinositol 3-kinase kinase. Here, we investigated the involvement of signal transduction pathways in efficient infection. Protein synthesis is not required for events leading to the transcription of the viral genome, suggesting that the early stages of infection do not depend on the expression of novel cell genes and consistent with the Wp promoter being the first viral promoter used upon infection. Since the stimulation of cells with gp340/220 leads to an increase in the level of CD19 tyrosine phosphorylation, we investigated the potential contribution of both tyrosine and phosphatidylinositol 3-kinase kinases to efficient infection. Both kinases contribute to the posttranscriptional control of viral gene expression following infection, but neither is required for the entry or initial transcription of the virus. Thus, it appears that EBV exploits a host signal transduction pathway to efficiently infect primary cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543582      PMCID: PMC189395     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.

Authors:  G R Nemerow; C Mold; V K Schwend; V Tollefson; N R Cooper
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

2.  An Epstein-Barr virus transcript from a latently infected, growth-transformed B-cell line encodes a highly repetitive polypeptide.

Authors:  S H Speck; A Pfitzner; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

3.  Control of human B-lymphocyte replication. II. Transforming Epstein-Barr virus exploits three distinct viral signals to undermine three separate control points in B-cell growth.

Authors:  J Gordon; L Walker; G Guy; G Brown; M Rowe; A Rickinson
Journal:  Immunology       Date:  1986-08       Impact factor: 7.397

4.  Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site.

Authors:  J Sample; M Hummel; D Braun; M Birkenbach; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

5.  Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus.

Authors:  J H Pope; M K Horne; W Scott
Journal:  Int J Cancer       Date:  1968-11-15       Impact factor: 7.396

6.  DNA sequence and expression of the B95-8 Epstein-Barr virus genome.

Authors:  R Baer; A T Bankier; M D Biggin; P L Deininger; P J Farrell; T J Gibson; G Hatfull; G S Hudson; S C Satchwell; C Séguin
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

7.  Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process.

Authors:  G R Nemerow; N R Cooper
Journal:  Virology       Date:  1984-01-15       Impact factor: 3.616

8.  Epstein-Barr virus RNA. V. Viral RNA in a restringently infected, growth-transformed cell line.

Authors:  W King; A L Thomas-Powell; N Raab-Traub; M Hawke; E Kieff
Journal:  J Virol       Date:  1980-11       Impact factor: 5.103

9.  p53 is frequently mutated in Burkitt's lymphoma cell lines.

Authors:  P J Farrell; G J Allan; F Shanahan; K H Vousden; T Crook
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598

10.  Early events in Epstein-Barr virus infection provide a model for B cell activation.

Authors:  D A Thorley-Lawson; K P Mann
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

View more
  20 in total

1.  Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus.

Authors:  P R Smith; O de Jesus; D Turner; M Hollyoake; C E Karstegl; B E Griffin; L Karran; Y Wang; S D Hayward; P J Farrell
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus.

Authors:  L C Spender; E J Cannell; M Hollyoake; B Wensing; J M Gawn; M Brimmell; G Packham; P J Farrell
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 3.  EBV Persistence--Introducing the Virus.

Authors:  David A Thorley-Lawson
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

4.  High-potentiality preliminary selection criteria and transformation time-dependent factors analysis for establishing Epstein-Barr virus transformed human lymphoblastoid cell lines.

Authors:  I-C Chang; J-Y Wu; H-I Lu; H-W Ko; J-L Kuo; C-Y Wang; P-S Shen; S-M Hwang
Journal:  Cell Prolif       Date:  2006-12       Impact factor: 6.831

Review 5.  Epstein-Barr virus entry.

Authors:  Lindsey M Hutt-Fletcher
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

Review 6.  Heterogeneous pathways of maternal-fetal transmission of human viruses (review).

Authors:  A Saleh Younes; Márta Csire; Beatrix Kapusinszky; Katalin Szomor; Mária Takács; György Berencsi
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

7.  The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-kappaB during infection.

Authors:  A D Yurochko; E S Hwang; L Rasmussen; S Keay; L Pereira; E S Huang
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

8.  Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes.

Authors:  Wangrong Wen; Dai Iwakiri; Koji Yamamoto; Seiji Maruo; Teru Kanda; Kenzo Takada
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

9.  Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.

Authors:  Clemens Busse; Regina Feederle; Martina Schnölzer; Uta Behrends; Josef Mautner; Henri-Jacques Delecluse
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

10.  Use of gHgL for attachment of Epstein-Barr virus to epithelial cells compromises infection.

Authors:  Corina M Borza; Andrew J Morgan; Susan M Turk; Lindsey M Hutt-Fletcher
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.